XCUR

Exicure, Inc.
CAPPED RATING

Exicure, Inc. (XCUR) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-). The rating has held at C- for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.4
EV / EBITDA -0.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -21.7%
Price Return 12M -70.0%
Catalyst Signal 0.00
Market Cap $7.1M
TTM Revenue N/A
Price / Sales N/A
ROE -168.4%

Historical Factor Score Progression

Held C- for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) C+ (2.5) D- (0.9) D+ (1.6) C+ (2.6) C- (2.0)
2026-11-08 C+ (2.5) C+ (2.5) D- (0.9) D (1.3) C+ (2.6) C- (2.0)
2026-11-01 C+ (2.5) C+ (2.5) D- (1.0) D (1.2) C+ (2.7) C- (2.0)
2026-10-25 C+ (2.5) C+ (2.5) D- (1.0) D- (1.0) C+ (2.6) C- (1.9)
2026-10-18 C+ (2.5) C+ (2.5) D- (1.0) D- (1.0) C+ (2.6) C- (1.9)
Page 1 of 3